The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Drug Makers Inconsistent in Sharing Clinical Trial Data

Drug Makers Inconsistent in Sharing Clinical Trial Data

November 19, 2015 • By Lisa Rapaport

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters Health)—Drug companies are inconsistent about disclosing data related to clinical trials of new medicines, a new report says.

You Might Also Like
  • Authors Should Share Clinical Trial Data
  • Creative Online Strategies for Rheumatologists to Track & Assess Emerging Clinical Trial Data
  • Second Indian Firm Under Fire for Shoddy Clinical Drug Trials

Researchers examined publicly available data on clinical trials for 15 new medicines from 10 companies that were cleared for sale by the U.S. Food and Drug Administration in 2012.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Two of the companies disclosed all trials and complied with legal disclosure requirements for medicines approved that year, according to the study published online Nov. 12 in BMJ Open.

But almost half of all the reviewed drugs had at least one undisclosed advanced drug trial involving human participants, the study found.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Your physician prescribes your drugs based on prescription guidelines on the labels, and these are based on publicly available evidence,” says lead study author Jennifer Miller, an ethics researcher at New York University Langone Medical Center. “It is nearly impossible to have evidence-based medicine without all of the evidence.”

To assess transparency in clinical trials, Miller and colleagues reviewed publicly available information on drugs approved by the FDA that were sponsored by the 20 pharmaceutical companies with the highest market value.

The analysis included drugs for cancers of the breast, colon and rectum, skin, kidney and blood, as well as for HIV, tuberculosis, multiple sclerosis and rare genetic disorders. Researchers also looked at trials for a meningitis vaccine and an anti-clotting drug.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

For all of the drugs combined, the researchers examined data on 318 trials involving almost 100,000 people.

Only 57% of the trials for each drug were typically registered properly, and only 20% of the final results were reported on ClinicalTrials.gov, a database maintained by the National Library of Medicine at the National Institutes of Health.

Just 56% of the results were published in academic journals and only 65% were published or had their results reported in some meaningful way, the analysis found.

Limitations of the study include its use of data from a single year, and its focus only on large pharmaceutical companies, the authors acknowledge. The research team is in the process of expanding their analysis to add more years and include smaller companies as well as drug development at academic centers, the authors note.

While the nuances of clinical trial reporting and publication may seem esoteric, the quality of public information has a big impact on patients, said Dr. Andrew Prayle, a researcher at the University of Nottingham in the U.K. who wasn’t involved in the study.

Pages: 1 2 | Single Page

Filed Under: Drug Updates, Pharma Co. News Tagged With: clinical trials, data, FDA, Food and Drug Administration, pharmaceutical company, Pharmaceutical Research

You Might Also Like:
  • Authors Should Share Clinical Trial Data
  • Creative Online Strategies for Rheumatologists to Track & Assess Emerging Clinical Trial Data
  • Second Indian Firm Under Fire for Shoddy Clinical Drug Trials
  • French Prosecutors Open Probe into Fatal Drug Trial

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.